Covovax
-
{
- All
- News
- Videos
-
Current Covid Strain Mild, 5-6 Million Covovax Doses Made: Adar Poonawalla
The prevalent strain of COVID-19 is mild and the Serum Institute of India (SII) has already produced five to six million doses of the Covovax vaccine, said the company's chief executive officer Adar Poonawalla.
-
Covovax Booster Dose To Be Available On CoWIN, Cost Rs 225: Report
Union Health Minister Mansukh Mandaviya is learnt to have approved the inclusion of Serum Institute's Covovax on the CoWIN portal as a heterologous booster dose for adults, official sources said on Monday.
-
Serum Institute Seeks Inclusion Of Covovax On CoWIN As Booster Dose For Adults
The DCGI approved Covovax for restricted use in emergency situations in adults on December 28, 2021, in the 12-17 age group on March 9, 2022, and in the 7-11 age group on June 28, 2022, subject to certain conditions.
-
Serum Institute Seeks Inclusion Of Covid Jab 'Covovax' In CoWIN Portal
Serum Institute of India has written to the Union Health Ministry seeking the inclusion of its Covid vaccine Covovax in the CoWIN portal as a heterologous booster dose for adults, official sources said on Wednesday.
-
Centre's Panel Recommends Market Clearance To Covovax As Covid Booster: Report
An expert panel of the central drug regulatory authority has recommended market authorisation for Serum Institute of India's Covid vaccine Covovax as a heterologous booster dose for adults, Press Trust of India reported.
-
Covovax To Get Approval As Covid Booster In 10-15 Days: Adar Poonawalla
Serum Institute of India chief executive officer Adar Poonawalla on Sunday said its Covovax vaccine will get approval as a booster in the next 10 to 15 days, adding it works well against the Omicron variant of coronavirus.
-
Serum Institute's Covid Vaccine Covovax Cleared For 7-11 Age Group
The Drugs Controller General of India (DCGI) on Tuesday approved Serum Institute's COVID-19 vaccine Covovax for restricted emergency use in children aged 7 to 11 years subject to certain conditions, official sources said.
-
"Covovax Available For Everyone Above 12 Years", Tweets Adar Poonawalla
Chief Executive Officer of Pune based Serum Institute of India Adar Poonawalla on Wednesday clarified that the COVID-19 vaccine Covovax is available for everyone above the age of 12 years.
-
Covovax Vaccine Now Available For 12-17 Age Group At Private Centres
Children aged 12 to 17 years can now get the Serum Institute's coronavirus vaccine Covovax at private centres with a provision for it being made on the CoWIN portal, official sources said on Monday.
-
Immunisation Panel Approves Covovax Vaccine For 12-17 Age Group: Report
National Technical Advisory Group on Immunisation (NTAGI) on Friday approved Serum Institute of India's Covovax COVID-19 vaccine for the age group 12-17, said sources.
-
Covovax First Indian Covid Vaccine To Be Sold In Europe: Adar Poonawalla
Serum Institute's Adar Poonawalla said Covovax is the first vaccine made in India to be sold in Europe.
-
COVID-19 Working Group To Review Data For Covovax Vaccine On Friday: Report
The COVID-19 working group of the National Technical Advisory on Immunisation (NTAGI) will be reviewing the data of Serum Institute of India's vaccine - Covovax for use for children and adults, on April 1, sources said today.
-
Covovax Gets Emergency Use Approval For Children Above 12 Years
India's drug regulator has granted restricted emergency use authorisation to Serum Institute of India's COVID-19 vaccine Covovax for the 12-17 years age group subject to certain conditions, official sources said on Wednesday.
-
Serum Institute Seeks Nod For Phase-3 Study Of Covovax As Booster Dose In Adults
Serum Institute of India has sought permission from India's drug regulator to conduct a phase-3 study of its COVID-19 vaccine Covovax as a booster dose in adults, official sources said on Sunday.
-
Serum Institute Seeks Emergency Use Approval Of Covid Vaccine Covovax In South Africa
Novavax and Serum Institute of India (SII) announced a regulatory submission to the South African Health Products Regulatory Agency for emergency use authorization (EUA) of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine
-
Current Covid Strain Mild, 5-6 Million Covovax Doses Made: Adar Poonawalla
The prevalent strain of COVID-19 is mild and the Serum Institute of India (SII) has already produced five to six million doses of the Covovax vaccine, said the company's chief executive officer Adar Poonawalla.
-
Covovax Booster Dose To Be Available On CoWIN, Cost Rs 225: Report
Union Health Minister Mansukh Mandaviya is learnt to have approved the inclusion of Serum Institute's Covovax on the CoWIN portal as a heterologous booster dose for adults, official sources said on Monday.
-
Serum Institute Seeks Inclusion Of Covovax On CoWIN As Booster Dose For Adults
The DCGI approved Covovax for restricted use in emergency situations in adults on December 28, 2021, in the 12-17 age group on March 9, 2022, and in the 7-11 age group on June 28, 2022, subject to certain conditions.
-
Serum Institute Seeks Inclusion Of Covid Jab 'Covovax' In CoWIN Portal
Serum Institute of India has written to the Union Health Ministry seeking the inclusion of its Covid vaccine Covovax in the CoWIN portal as a heterologous booster dose for adults, official sources said on Wednesday.
-
Centre's Panel Recommends Market Clearance To Covovax As Covid Booster: Report
An expert panel of the central drug regulatory authority has recommended market authorisation for Serum Institute of India's Covid vaccine Covovax as a heterologous booster dose for adults, Press Trust of India reported.
-
Covovax To Get Approval As Covid Booster In 10-15 Days: Adar Poonawalla
Serum Institute of India chief executive officer Adar Poonawalla on Sunday said its Covovax vaccine will get approval as a booster in the next 10 to 15 days, adding it works well against the Omicron variant of coronavirus.
-
Serum Institute's Covid Vaccine Covovax Cleared For 7-11 Age Group
The Drugs Controller General of India (DCGI) on Tuesday approved Serum Institute's COVID-19 vaccine Covovax for restricted emergency use in children aged 7 to 11 years subject to certain conditions, official sources said.
-
"Covovax Available For Everyone Above 12 Years", Tweets Adar Poonawalla
Chief Executive Officer of Pune based Serum Institute of India Adar Poonawalla on Wednesday clarified that the COVID-19 vaccine Covovax is available for everyone above the age of 12 years.
-
Covovax Vaccine Now Available For 12-17 Age Group At Private Centres
Children aged 12 to 17 years can now get the Serum Institute's coronavirus vaccine Covovax at private centres with a provision for it being made on the CoWIN portal, official sources said on Monday.
-
Immunisation Panel Approves Covovax Vaccine For 12-17 Age Group: Report
National Technical Advisory Group on Immunisation (NTAGI) on Friday approved Serum Institute of India's Covovax COVID-19 vaccine for the age group 12-17, said sources.
-
Covovax First Indian Covid Vaccine To Be Sold In Europe: Adar Poonawalla
Serum Institute's Adar Poonawalla said Covovax is the first vaccine made in India to be sold in Europe.
-
COVID-19 Working Group To Review Data For Covovax Vaccine On Friday: Report
The COVID-19 working group of the National Technical Advisory on Immunisation (NTAGI) will be reviewing the data of Serum Institute of India's vaccine - Covovax for use for children and adults, on April 1, sources said today.
-
Covovax Gets Emergency Use Approval For Children Above 12 Years
India's drug regulator has granted restricted emergency use authorisation to Serum Institute of India's COVID-19 vaccine Covovax for the 12-17 years age group subject to certain conditions, official sources said on Wednesday.
-
Serum Institute Seeks Nod For Phase-3 Study Of Covovax As Booster Dose In Adults
Serum Institute of India has sought permission from India's drug regulator to conduct a phase-3 study of its COVID-19 vaccine Covovax as a booster dose in adults, official sources said on Sunday.
-
Serum Institute Seeks Emergency Use Approval Of Covid Vaccine Covovax In South Africa
Novavax and Serum Institute of India (SII) announced a regulatory submission to the South African Health Products Regulatory Agency for emergency use authorization (EUA) of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine
